Tyra Biosciences (TYRA) Plunges 19.7% on Q2 Earnings: A Bloodbath or a Buying Opportunity for FGFR3 Bets?

Summary
• Tyra Biosciences (TYRA) closed at $26.13, down a staggering 19.67% on August 5, 2026.

• Q2 2026 net loss widened to $45.6 million, driven by surging R&D expenses.

• Cash reserves stand at $353.9 million, providing a runway through the second half of 2028.

• The stock traded between an intraday high of $30.587 and a low of $25.985, reflecting intense selling pressure.

Tyra Biosciences faced a brutal session today as the market digested a wider-than-expected quarterly loss and escalating development costs. Despite the headline miss, the company's robust balance sheet and upcoming SURF302 data readout in September remain the critical focal points for institutional positioning.
R&D Burn and Q2 Miss Spark Sell-Off
The precipitous 19.67% decline in TYRA's share price was triggered directly by the release of its Second Quarter 2026 financial results. Investors reacted negatively to the widening net loss, which jumped to $45.6 million from $28.1 million in the prior year period. This deterioration was primarily fueled by a massive 61% year-over-year increase in Research and Development (R&D) expenses, which climbed to $39.2 million from $24.3 million. These higher costs are attributable to the expansion of clinical trials for oral dabogratinib across the SURF303, SURF302, and BEACH301 studies, alongside headcount growth. Furthermore, General and Administrative (G&A) expenses rose to $9.8 million from $7.1 million, compounding the headline miss and eroding investor sentiment in the short term.

Technical Support Levels and Bearish Option Plays
The technical landscape for Tyra Biosciences is currently fraught with downside risk, as the stock has decisively broken below key moving averages and support zones. Here is the current technical snapshot:

• 200-Day Moving Average: $29.05 (Below - Strong Resistance)

• 30-Day Moving Average: $31.59 (Below - Short-term weakness)

• RSI (14): 50.80 (Neutral - No immediate oversold bounce)

• MACD: 0.25 (Positive but narrowing - Momentum fading)

The breakdown below the 200-day moving average at $29.05 and the 30-day average at $31.59 confirms a shift from a long-term ranging market to a distinct short-term bearish trend. The Relative Strength Index (RSI) hovering near 50.80 indicates that the stock is neither oversold nor overbought, suggesting there is no technical justification for an immediate violent bounce. Traders should watch the 200-day support zone of $30.90–$31.41, which has now flipped to heavy resistance. While the broader biotech sector saw mixed signals today with Vertex Pharmaceuticals (VRTX) leading with a modest 0.34% gain, TYRA is isolated in its decline. For leveraged exposure, the Direxion Daily S&P Biotech Bull 3X ETF (LABU) rose 1.60%, highlighting that TYRA's drop is idiosyncratic to its earnings profile rather than sector-wide.

Based on the provided options chain, two contracts stand out for a bearish or high-leverage short-term trade, selected for their balance of leverage, liquidity, and volatility:

• Contract: TYRA20260821P25 (Put)

• Expiration: August 21, 2026

• Strike Price: $25.00

• Turnover: $8,220

• Leverage Ratio: 26.18%

• Delta: -0.346

• Theta: -0.0155

• Gamma: 0.0933

• Implied Volatility Ratio: 70.00%

• IV (30-day): 70% (High - Reflects near-term uncertainty)

• Leverage (26.18%): 26x price sensitivity

• Delta (-0.346): Moderate downside exposure

• Theta (-0.0155): Time decay of $0.0155/day

• Gamma (0.0933): High price sensitivity

This contract offers the highest liquidity in the near-term chain with $8,220 in turnover. The 70% IV ratio is elevated but not extreme, offering a premium-rich environment for sellers or buyers seeking protection. The high gamma (0.0933) means the option price will accelerate rapidly as the stock moves lower, maximizing leverage for a bearish bet.

• Contract: TYRA20261120C20 (Call)

• Expiration: November 20, 2026

• Strike Price: $20.00

• Turnover: $1,220

• Leverage Ratio: 2.15%

• Delta: 0.786

• Theta: -0.0402

• Gamma: 0.0107

• Implied Volatility Ratio: 191.24%

• IV (191.24%): Very High - Deep OTM speculation

• Leverage (2.15%): 2x price sensitivity

• Delta (0.786): High directional exposure

• Theta (-0.0402): Time decay of $0.0402/day

• Gamma (0.0107): Moderate price sensitivity

While this is a Call option, the extremely deep In-The-Money (ITM) nature (Delta 0.786) and low strike ($20) make it behave almost like the stock itself. However, given the bearish technicals, this contract is included only to highlight the extreme IV (191%) available in longer-dated contracts, signaling that the market is pricing in significant volatility. For a pure directional play, the Put offers better risk/reward.

Options Payoff Calculation Primer: Assuming a 5% downside scenario where TYRA drops from $26.13 to $24.82:
- TYRA20260821P25 Payoff: max(0, 25.00 - 24.82) = $0.18 intrinsic value per share. This demonstrates the limited intrinsic value at a 5% drop, highlighting the need for a sharper move to realize profits.

If $26.00 breaks, TYRA20260821P25 offers accelerated downside potential with high gamma.

Hold Cash, Wait for SURF302 Clarity
The current sell-off is a rational reaction to increased burn rates, but the long-term thesis remains intact due to the $353.9 million cash runway. However, the technical breakdown below the 200-day moving average suggests caution is warranted until the September SURF302 data readout provides clinical confirmation. Investors should avoid catching the falling knife immediately. Instead, monitor the $25.00 psychological support level. Watch for a sustained break below $26.00 or a rebound above $29.05 to gauge institutional interest. Meanwhile, keep an eye on sector leader Vertex Pharmaceuticals (VRTX), which gained 0.34% today, providing a benchmark for biotech resilience amidst TYRA's turbulence.